Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 36 of 36 entries
View as:

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

Phase: N/A Priority: Normal
NCT ID: NCT01510769 Org: User:
Start: 01/31/12 End: 06/30/14 Due: 06/30/15

RDEA3170 Tablet and Capsule Bioavailability Study

Phase: N/A Priority: Normal
NCT ID: NCT02448368 Org: User:
Start: 05/01/15 End: 01/29/16 Due: 01/29/17

Open-Label Lesinurad Monotherapy Extension Study in Gout

Phase: N/A Priority: Normal
NCT ID: NCT01650246 Org: User:
Start: 08/31/12 End: 08/31/14 Due: 08/31/15

A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout

Phase: N/A Priority: Normal
NCT ID: NCT00741442 Org: User:
Start: 07/31/08 End: 09/30/09 Due: 09/30/10

Combining Lesinurad With Allopurinol in Inadequate Responders

Phase: N/A Priority: Normal
NCT ID: NCT01510158 Org: User:
Start: 01/31/12 End: 08/31/14 Due: 08/31/15

Single and Multiple Dose Study in Japanese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01872832 Org: User:
Start: 06/30/13 End: 11/30/13 Due: 11/30/14

Gout Dose Response Study

Phase: N/A Priority: Normal
NCT ID: NCT00955981 Org: User:
Start: 07/31/09 End: 09/30/11 Due: 09/30/12

IVIVR Assessing PK Parameters Used to Establish Bioequivalence

Phase: N/A Priority: Normal
NCT ID: NCT02398448 Org: User:
Start: 04/30/15 End: 09/30/15 Due: 09/30/16

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

Phase: N/A Priority: Normal
NCT ID: NCT02888054 Org: User:
Start: 08/30/16 End: 02/01/17 Due: 02/01/18

DECT Study in Allopurinol-Treated Gout Patients

Phase: N/A Priority: Normal
NCT ID: NCT02393560 Org: User:
Start: 04/30/15 End: 10/31/16 Due: 10/31/17

Lesinurad Tablet Bioequivalence

Phase: N/A Priority: Normal
NCT ID: NCT02127775 Org: User:
Start: 04/30/14 End: 07/31/14 Due: 07/31/15